Skip to main content

Table 2 Adjuvant chemotherapy regimens and toxicity profile

From: Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis

 

N (%)

Regimen

 

 Carboplatin-vinorelbine

24 (80)

 Cisplatin-vinorelbine

5 (17)

 Carboplatin-gemcitabine

1 (3)

Number of cycles

 

 1

6 (20)

 2

2 (7)

 3

3 (10)

 4

19 (63)

Discontinuation

8 (27)

Treatment-related AEs1

 

 Anemia

20 (67)

 Neutropenia

18 (60)

 Febrile neutropenia

5 (17)

 Thrombocytopenia

9 (30)

 Creatinine increase

4 (13)

 Transaminase increase

4 (13)

  1. AEs, adverse events
  2. 1Detailed information about treatment-related AEs missing for 4 patients
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us